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Abstract: To modulate T cell function for cancer therapy one challenge is to selectively 
attenuate regulatory but not conventional CD4+ T cell subsets (Treg and Tconv). In this 
study we show how a functional dichotomy in Class IA PI3K isoforms in these two subsets 
of CD4+ T cells be exploited to target Treg while leaving Tconv intact. Studies employing 
isoform-specific PI3K inhibitors and a PI3Kδ-deficient mouse strain revealed that PI3Kα 
and PI3Kβ were functionally redundant with PI3Kδ in Tconv. Conversely, PI3Kδ was 
functionally critical in Treg, acting there to control TCR signaling, cell proliferation and 
survival. Notably, in a murine model of lung cancer, co-administration of a PI3Kδ-specific 
inhibitor with a tumor-specific vaccine decreased numbers of suppressive Treg and 
increased numbers of vaccine-induced CD8 T-cells within the tumor microenvironment, 
eliciting potent anti-tumor efficacy. Overall, our results offer a mechanistic rationale to 
employ PI3Kδ inhibitors to selectively target Treg and improve cancer immunotherapy.  
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Introduction: 
Decreasing the numbers and/or function of regulatory T-cells (Tregs) is needed to produce better 
therapeutic outcomes for cancer patients. The ideal Treg-targeting approach should be selective 
to maintain specifically in the frame of cancer immune therapy for which maintenance of a 
potent effector arm of the immune system is vital. Several approaches have been tested to deplete 
or inactivate Tregs[1-4], but these strategies do not provide selective inhibition of Tregs and may 
result in a decrease of effector T-cells [5].  
Understanding the signaling pathways regulating conventional T-cells (Tconvs) and Tregs 
activation, function and survival can help to design drugs that could selectively modulates Tregs 
and Tconvs.  PI3K-Akt is an important pathway involved in signaling downstream of the T-cell 
receptor (TCR) and regulates proliferation, cell metabolism and cell growth, and as we have 
previously shown, it is differentially regulated in these CD4 T-cell subsets [6-11].  Furthermore, 
it was recently reported that inhibition of the PI3Kδ isoform results in a decrease in Tregs 
number and delayed tumor growth in animal models [12]. However, the role of the PI3K 
isoforms in the regulation of Tregs and Tconvs is not fully understood. Here we hypothesized 
that there may be a differential role of Class IA PI3K isoforms in Tconv and Treg cell regulation.  
The Class IA PI3K family consists of a heterodimeric complex of 110-kD catalytic subunits, 
p110α, β, or δ, with a regulatory subunit (p85α, p55α, p50α, p85β, or p55γ) [7, 13, 14]. The PI3K 
110α and β subunits are ubiquitously expressed while p110δ expression is restricted to 
hematopoietic cells [7]. Cell death by apoptosis is a major regulator of hematopoietic cell 
homeostasis. B-cell lymphoma 2 (BCL-2) family proteins, which have either pro- or anti-
apoptotic activities, have been studied intensively for the past decade owing to their importance 
in the regulation of apoptosis[1].  Myeloid cell leukemia 1 (Mcl-1), an anti-apoptotic member of 
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the Bcl-2 family [2], is critical for survival of Treg cells, and it has been shown that, the loss of 
this antiapoptotic protein caused fatal autoimmunity [3]. Mcl-1 is tightly regulated by glycogen 
synthase kinase. The glycogen synthase kinase 3 (GSK3α/GSK3β) is a ubiquitously expressed 
serine/threonine kinase, and regulates a wide variety of functions, including metabolism, cell 
proliferation, cell differentiation and apoptosis and is reported to be required for Mcl-1 
degradation [4]. GSK3β is a downstream target of PI3k-Akt signaling pathway and usually 
remains active in cells; however PI3K induced activation of Akt results in the phosphorylation 
(S9) of GSK-3β that inhibits its activity [5, 6]. The differential role of class IA PI3K isoform in 
regulating the survival and apoptosis of Tregs and Tconvs has not been elucidated yet.   
Here, we report that Class IA PI3K isoforms play different roles in Tregs and Tconvs. We found 
that in contrast to Tregs that are primarily dependent on the PI3Kδ isoform, in Tconvs PI3Kδ is 
necessary,  and in contrast to the situation in Tregs, PI3Kα and β provide a redundant pathway to 
PI3Kδ, ensuring the presence of alternative pathways to provide a robust effector function when 
needed to eliminate any assault on the immune system. We have also evaluated the translation of 
these findings in vivo on therapeutic efficacy by assessing the effect of treatment with PI3Kδ 
inhibitor on the antitumor immune response.Our findings clarify the role of the PI3K isoforms in 
CD4 T-cell TCR signaling and offer a further understanding of the development of selective 
strategies for the modulation of different CD4 T-cell subsets in the frame of immunotherapy.  
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Material and Methods:  
 
Animals: C57BL/6 female 6-8-week-old mice were purchased from Jackson Laboratory (Bar 
Harbor, ME). P110delta-PI3K-D910A (kinase-dead) PI3Kδ KO mice was purchased from 
Charles River, Wilmington, MA and bred under pathogen-free conditions in the Augusta 
University animal facility. Foxp3-GFP mice were housed and bred under pathogen-free 
conditions in the Augusta University animal facility. All procedures were carried out in 
accordance with approved institutional animal protocols.  
Antibodies: All fluorophore-labeled antibodies were purchased from BD Biosciences (San Jose, 
CA). 
PI3K inhibitors: A66 (PI3Kα inhibitor; IC50 of 32nM) [15, 16], TGX-221 (PI3Kβ inhibitor; 
IC50 of 5nM) [16, 17], and CAL-101  (PI3Kδ inhibitor; IC50 of 2.5nM)[18], GDC-0941 (PAN 
PI3K inhibitor) [19] were purchased from Selleckchem, (Houston, TX) The IC50 for each 
isoform is listed in (Supplementary Table 1). 
 
Western Blotting (WB):  
Total protein lysates were collected in RIPA buffer. Forty micrograms of lysates were run on 
SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were probed with 
primary antibodies (1:1000 dilutions) overnight at 4oC and incubated with secondary antibodies 
(1:5000 dilution) for one hour at room temperature. Chemiluminescence was performed with 
Pierce reagents (Rockford, IL).  
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T-cell Stimulation Flow cytometry analysis and in vitro CellTrace TM Viole T-cell 
Proliferation (VCT-Viole T-cell Trace) assay:  
Sorted Tregs and Tconvs were labeled with CellTrace TM Viole T-cell Proliferation stain (VCT) 
according to the manufacturer’s protocol (Life Technologies, NY). Cells were stimulated with 
and without inhibitors in the presence of 10μg/mL plate-bound anti-CD3, 2.5μg/mL soluble anti-
CD28, and 100 IU/mL IL-2. For negative control (non-stimulated), cells were cultured in 100 
IU/mL IL-2.  After 3 days, cells were stained with fixable live/dead cell stain (Life Technologies, 
NY), fixed and permeabilized using the mouse Foxp3 buffer kit according to the manufacturer’s 
instructions (BD Bioscience, San Jose, CA) and stained with anti-CD4-FITC and anti-Foxp3-
AlexaFluor 647. For pAkt (S473) and pS6 (S244) analysis, the signal was amplified using a 
biotin-conjugated donkey anti-rabbit antibody (BD Biosciences) and streptavidin-PE. After 
staining, cells were acquired on a LSRII SORP flow cytometer (BD Biosciences) and analyzed 
using FlowJo software (Tree Star).  
 
Tumor cell lines:  
TC-1 cell line was a gift from Prof. T.C. Wu, Johns Hopkins University, Department of 
Pathology, and Baltimore, MD [20]. Briefly, TC-1 tumor cell line was generated from lung 
epithelial cells immortalized with HPV16 E6 and E7. Cell line authentication was carried out by 
morphology and flow cytometry 4 months prior to the first submission of the manuscript [21].  
Cell lines used in this study were routinely tested for contamination by PCR. All cell culture 
stocks were stored in liquid nitrogen. The growth of tumors formed from these cells is enhanced 
by Tregs.  
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In vivo experiments: C57BL/6 Mice were injected subcutaneously (s.c.) with 70,000 TC-1 
tumor cells and monitored for development of tumors. On day 10-12, when tumor size reached 
3-5mm in diameter, mice were treated with a single intraperitoneal (i.p.) injection of A66, TGX-
221, or CAL-101 at 2 or 10mg/kg. The control group received 10% DMSO in water (vehicle). 
Mice were then sacrificed 3 or 6 days after treatment.  Splenocytes were harvested, stained for 
CD3, CD4, CD8, and Foxp3 and analyzed by flow cytometry (LSRII SORP).  
Alternatively, mice injected with TC-1 were monitored for development of tumor. On day 10-12, 
when tumor size reached 3-5mm in diameter, spleens and tumors from the pre-treatment group 
of animals were used to examine the T-cell population before starting the treatment (baseline). 
Animals were treated with either CAL-101 (10mg/kg) or 10% DMSO in water (vehicle) starting 
on the 12th day following TC-1 implantation for the next 14 days with three-day interval. All 
groups were euthanized on day 26 of TC-1 implantation for evaluation of the T-cell subsets, and 
their proliferation was measured by Ki67 expression. 
 
Tumor implantation and treatment  
For both therapeutic and immunology experiments 70,000 TC-1 cells were inoculated s.c. on day 
0. The growth of tumors formed from these cells is enhanced by Tregs. Vaccine was given 
weekly s.c. starting on day 10-12 after tumor implantation when tumor diameter reached 3-5 
mm. For therapeutic experiments vaccine was given weekly throughout the experiment. CAL-
101 treatment was provided on the day when tumor size reached 3-4mm 5-6 day before 
vaccination. CAL-101 was given every third day for entire duration of treatment. Total of four 
groups (I) No Treatment, (II) CAL-101, (III) Vaccine, and (IV) combination of Vaccine with 
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CAL-10   (n=5 for each group) of mice were utilized in these experiments. In these studies, 
tumor growth and survival was monitored. Tumors were measured every 3–4 days using digital 
calipers, and tumor volume was calculated using the formula V= (W2*L)/2, whereby V is the 
volume, L is the length (longer diameter) and W is width (shorter diameter). Mice were 
sacrificed when moribund or if tumor volume reached 1.5 cm3. For immunology experiments 
mice were treated similarly and were sacrificed three days after the second immunization which 
ensured no significant differences existed in tumor size between different groups. Tumors were 
harvested for analysis of tumor infiltrating cells. 
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RESULTS 
Class IA PI3K isoform differentially regulate TCR signaling and proliferation of 
regulatory T-cells and Conventional T-cells 
We recently reported that several inhibitors that target PI3K and its downstream effector, Akt, 
selectively inhibit the in vitro proliferation of human and murine Treg when compared to Tconv. 
This selective decrease in Treg proliferation provided us with a potential strategy to modulate the 
Treg/Tconv balance in vivo[10].  However, the exact mechanism of PI3K/Akt regulation in these 
subtypes has not been fully elucidated. The differential sensitivity of Tregs and Tconvs could be 
an outcome of disparate expression level of the PI3K isoforms in Tregs and Tconvs.  We 
therefore checked the expression level of different PI3K isoforms in Tregs and Tconvs.  We 
found no significant differences in protein expression patterns of the PI3K subunits, p85α, 
p110α, p110β, or p110δ, between Tregs and Tconvs (Supplementary Figure S1).  To further 
explore the role of the PI3K isoforms in Tconvs and Tregs, we examined the effect of titrated 
concentrations of specific PI3K isoform inhibitors on the downstream signaling of this pathway 
in these CD4 T-cell subpopulations. FACS-sorted Tregs and Tconvs were activated in the 
presence or absence of specific inhibitors of PI3Kα (A66), PI3Kβ (TGX-221), or PI3Kδ 
(CAL101). The phosphorylation status of the downstream Akt was measured by flow cytometry 
(Supplementary Figure S2A and S2B). The range of used concentrations was selected based on 
the previously published IC50 of these inhibitors [15, 16, 18] (Supplementary Table 1). We did 
not detect any remarkable inhibition of pAkt (S473) in either Tregs or Tconvs at all the tested 
concentrations of either A66 or TGX-221 (Figure 1A, 1B and Supplementary Figure S3A, 
Supplementary S3B). In contrast, inhibition of the PI3Kδ isoform with CAL-101 significantly 
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mitigated the phosphorylation of Akt (S473) and Akt (T308) in Tregs but had no effect on 
Tconvs as shown in Figure 1C and Supplementary Figure S4, respectively. The effect was 
also reflected further downstream of the PI3K-Akt pathway, where the phosphorylation status of 
ribosomal protein (rp) S6 (pS244) in Tregs treated with CAL-101 was significantly inhibited 
(Figure 1D).   
To gain a more complete understanding of the differential role of class IA PI3K isoform in Tregs 
and Tconvs, we tested the effect of specific PI3K isoform inhibition on the proliferation of these 
T-cell subtypes. Using Class IA Isoform specific inhibitors, we found that inhibiting PI3Kα or 
PI3Kβ has no effect on either Tregs or Tconvs proliferation as shown in Supplementary figure 
Figure S5 A  & B, respectively. On the other hand, PI3Kδ inhibition led to a significant 
abrogation of Tregs proliferation in a concentration-dependent manner, without affecting Tconvs 
proliferation (Figure 1E). The findings were further confirmed using Tregs and Tconvs from 
mice with PI3Kδ inactive kinase (PI3Kδ KO). As expected, we found that the level of phospho-
Akt (S473) in Tregs obtained from PI3Kδ KO mice (Figure 1F) and their proliferation ability 
under TCR/IL-2 stimulation (Figure 1G) were significantly lower compared to Tregs from WT.  
Furthermore,  there was no significant differences in Tconvs obtained from the two mice strains.  
These data demonstrate that TCR signaling in Tregs is exclusively dependent on PI3Kδ but not 
on PI3Kα or PI3Kβ, while in Tconvs, no specific isoform was found to be dominant in TCR 
downstream signaling. 
To further validate these finding for therapeutic approached in immunotherapy, we tested the 
effect of PI3K isoforms inhibitors on human CD4 T-cell. Human Tregs and Tconvs were 
fractionated from PBMCs by fluorescence-activated cell sorting. Tregs were sorted based on 
expression of CD4+CD25HI, whereas Tconvs were identified as CD4+CD25–.  We first tested the 
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effect of PI3Kδ isoform inhibitors on the level of phosphorylated Akt (pAkt-S473) in Tregs and 
Tconv and on the proliferation of these two cells types.  We tested the effect of the PI3Kδ 
inhibitor after stimulation with anti-CD3/anti-CD28 in a 3-day culture in media containing 100 
IU/mL of IL2, with titrated amounts of CAL-101.  Similar to the effect on mouse cells, we found 
that PI3Kδ inhibition led to a significant decreased level of pAkt in Tregs but not Tconv and 
significant abrogation of Tregs proliferation, without affecting Tconvs, in a concentration-
dependent manner (Figure 1H and 1I). Based on the reproducibility of the data in human, we 
believe that using specific PI3Kδ inhibitor would be a reasonable approach to enhance cancer 
immunetherapy. 
 
PI3K isoform differentially regulate the frequency of T-cell subsets in tumor bearing mice 
After demonstrating that the inhibition of PI3Kδ isoform but not PI3Kα or β impairs TCR 
signaling in Tregs and not Tconvs in vitro, we next tested whether this specificity is translated in 
an in vivo model. We selected TC-1 [20] syngeneic mouse model which is a Treg-dependent 
tumor model [22], and the frequency of Tregs increases significantly in tumor bearing mice 
compared to non-tumor mice (Figure 2B).  In addition, TC-1 expresses PI3Kα and PI3Kβ, but 
do not express detectable levels of p110δ (Figure 2C). Consequently, specific PI3K isoform 
inhibitors were tested in the TC-1 syngeneic mouse tumor model. Mice were treated with a 
single dose of the inhibitors 10 days after tumor implantation (Figure 2A). Mice were sacrificed 
3 or 6 days after treatment and the level of splenic Tregs was assessed. We found that inhibition 
of PI3Kδ with CAL-101 led to a dose dependent inhibition of Tregs in the spleen with significant 
reduction at 10mg/Kg on day 3 after treatment (Figure 2D). In contrast, inhibition of PI3Kα or β 
had no significant effects on splenic Tregs with either a 2mg/kg or 10 mg/kg dose on day 3 
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(Figure 2D) and day 6 (Figure 2E) after treatment. Considering the short half-life of CAL101 
(~1 hour [23]), not surprisingly, the level of Tregs returned to control levels on day 6 after 
treatment (Figure 2E). Importantly, we found that inhibition of PI3Kα, β or δ with either a 
2mg/kg or 10mg/kg dose of inhibitors had no significant effects on splenic CD4+, CD4+Foxp3– 
or CD8+ cells (Figure 2F, 2G and 2H) on day 3 after treatment. The level of CD4+ and CD8+ T-
cells was also not affected on day 6 by any of the PI3K inhibitors at either dose (data not shown). 
This indicates that PI3Kδ, but not PI3Kα or PI3Kβ inhibition reduces the number of Tregs and 
spares other T-cell subsets. Consistent with in vitro findings, we found that, in vivo Tregs is 
dependent on PI3Kδ exclusively but not on PI3Kα or PI3Kβ, while in Tconvs, no specific 
isoform was found to be functionally dominant. We next tested the impact of continuous 
treatment of CAL-101 (10mg/kg) on splenic T-cell population in TC-1 model. TC-1 injected 
(s.c.) mice were monitored for development of tumor. On day 12, when tumor size reached 3-
5mm in diameter, spleens from one group of animals were used to examine the percentage of 
Tregs (base line) before starting the treatment. Animals were treated with either CAL-101 or 
vehicle every 3 days total of five doses (Supplementary Figure S6A). Animals were sacrificed 
on day 26 after tumor implantation. As expected we observed that there was an increase in Tregs 
population in vehicle treated animals on day 26 compared to base-line (Supplementary Figure 
S6B). However, the continuous administration of CAL-101 at three day intervals significantly 
decreased the percentage of Tregs in CAL-101 treated mice compared to vehicle treated animals 
(Supplementary Figure S6B).  We also evaluated the effects of CAL-101 on effector T-cell 
subsets including CD4+ and CD8+ cells. We did not find any effects of CAL101 on percentage 
of CD4+Foxp3- (Supplementary Figure S6C) and CD3+CD8+ (Supplementary Figure S6D) 
cells. These observations suggest a schedule for CAL-101 administration for keeping the Tregs 
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at significantly low level without affecting the other T-cell populations. Thus, our data 
demonstrate that CAL-101 treatment selectively impaired the survival signal in Treg cells in 
vitro that could be correlated with decreasing their number in CAL-101 treated animals in vivo. 
As CAL-101 treatment selectively impaired proliferation of Treg cells in vitro, we investigated 
whether their proliferative capacity was reduced in vivo as well. We performed analyses of Ki67 
expression in response to CAL-101 administration. Treg cells from CAL-101 treated animals 
showed a decreased proliferative response as assessed by Ki67 staining (Supplementary Figure 
S6E).  The proliferation potential of effector T-cells (CD4+ and CD8+) from CAL-101 treated 
animals did not show any impaired proliferative response (Supplementary Figure S6F & S6G). 
This suggests that the selective reduction of Treg cells in CAL-101 treated animals could be a 
consequence of impaired survival signals as well as inhibition of proliferation. 
 
PI3Kα and PI3Kβ provides a redundant pathway to PI3Kδ in Tconvs for TCR signaling 
and proliferation 
Since our data demonstrate that downstream TCR signaling and proliferation of Tregs are 
dependent on PI3Kδ, while none of the inhibitors alone showed any effect on activation and 
proliferation in Tconvs, we next investigated whether the PI3K isoforms provide functional 
redundancy in Tconvs. To examine this, we tested whether the inhibition of all Class IA PI3K 
isoforms using the PAN inhibitor GDC (GDC-0941) affects downstream TCR signaling.  We 
found that the PAN inhibition of PI3K isoforms with GDC significantly mitigated the 
phosphorylation of Akt (S473) in Tconvs as shown in Figure 3A. The effect was also reflected 
downstream of the PI3K-Akt pathway, where the phosphorylation status of ribosomal protein S6 
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(Figure 3B) and proliferation (Figure 3C) in Tconvs treated with GDC was significantly 
inhibited. 
 To examine the role of each PI3K isoform in Tconvs, we tested whether the simultaneous 
inhibition of any two PI3K isoforms affects downstream TCR signaling.  We treated Tconvs 
with PI3K inhibitors specifically targeting 2 isoforms at a time: PI3Kα and PI3Kβ (A66+TGX-
221), PI3Kα and PI3Kδ (A66+CAL101), and PI3Kβ and PI3Kδ (TGX-221+CAL101).  We 
found that combining inhibition of both PI3Kα and PI3Kβ did not affect the phosphorylation of 
Akt and S6 (Figure 3D & E). As expected, there was no effect on proliferation of Tconvs either 
(Figure 3F). These findings show that PI3Kδ is sufficient for TCR signaling and proliferation of 
Tconvs.  On the other hand, combining PI3Kδ inhibitor with either PI3Kα or PI3Kβ inhibitor 
significantly reduced the levels of pAkt and pS6 (Figure 3D & E) and inhibited proliferation of 
Tconvs (Figure 3F). We further confirmed our data using T-cells lacking PI3Kδ obtained from 
PI3Kδ KO mice. As expected, we found that while proliferation of Tconvs from WT mice were 
not affected in presence of PI3Kα or PI3Kβ inhibitors (Figure 1E and 1F), proliferation of 
Tconvs from PI3Kδ KO mice was significantly inhibited in presence of either of these inhibitors 
(Figure 3G). Further, targeting both PI3Kα and PI3Kβ together, using A66 and TGX-221, did 
not inhibit the proliferation of Tconvs from WT mice. However, combined inhibition of PI3Kα 
and PI3Kβ (A66+TGX-221) significantly mitigated the proliferation of Tconvs from PI3Kδ KO 
mice (Figure 3G).  
Together, these findings show that PI3Kδ is sufficient for TCR signaling and proliferation of 
Tconvs.  However, in contrast to Tregs, in Tconvs, PI3Kα and PI3Kβ combined can compensate 
for the absence of PI3Kδ.  
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Class IA PI3K isoform differentially regulate the survival of Tregs through GSK-3β and 
Mcl-1 signaling pathway.  
 
Differential role of Class IA PI3K for regulation of TCR survival signaling in conventional 
CD4+Foxp3- cells and regulatory CD4+Foxp3+ cells has not been explored.   Since, the 
inhibition of individual PI3K isoforms does not affect Tconvs, and inhibition of only PI3Kδ 
decreases the frequency of Tregs in tumor bearing mice, we next tested whether their survival is 
affected in the presence of isoform specific inhibitors in vitro.  Cells were activated in vitro with 
and without inhibitors for 72hrs and the viability of Tregs and Tconvs was analyzed after 
treatments with different PI3K inhibitors using fixable live/dead cell stain (Life Technologies, 
NY).  Tregs and Tconvs showed no sign of reduced survival when PI3Kα or PI3Kβ was inhibited 
(Figure 4A & 4B), however, in contrast to Tconvs, the inhibition of PI3Kδ with CAL-101 
significantly decreased the survival of Tregs (Figure 4C). Interestingly, the survival of Tconvs 
was not effected in the presence of either of PI3K isoform specific inhibitor. These results 
indicated that Tregs survival is dependent on PI3Kδ and accordingly sensitive to its inhibition.  
to further confirm this we tested whether the inhibition of PI3Kδ induces apoptosis in Tregs. 
Using Annexin V binding assay, we found that frequency of Annexin V positive (apoptotic) cells 
increased with increasing concentrations of CAL-101 (Supplementary figure S7A).  
To understand the molecular mechanism by which PI3Kδ inhibition selectively induces 
apoptosis leading to reduced survival of Tregs, we next evaluated the effect of specific PI3K 
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isoform inhibition on the anti-apoptotic protein myeloid cell leukemia 1 (Mcl-1), which is critical 
for the survival of T-cells including Tregs [24] and is rapidly degraded when cells undergo 
apoptosis in response to various stimuli [25-28]. Mcl-1 can sequester direct activator BH3-only 
proteins, such as Bim, Bad and Puma and prevent them from activating Bak. In absence of Mcl-
1, Bak forms pore in the outer mitochondrial membrane (OMM) to release cytochrome c, 
activate caspases and induce apoptosis (Figure 4H). 
Accordingly, we tested the expression of Mcl-1 in Tregs and Tconvs treated with specific PI3K 
isoform inhibitors. We found that inhibition of PI3Kα or PI3Kβ does not affect the expression of 
Mcl-1 levels in Tregs or Tconvs (Figure 4D). Conversely, the inhibition of PI3Kδ by CAL-101 
remarkably decreases the expression of Mcl-1 in Tregs but has no effect on Tconvs (Figure 4E). 
These observations further indicate that that PI3Kδ selectively regulates the survival of Tregs 
through Mcl-1 pathway.  Since, the survival of Tconvs were not affected with either of isoform 
specific inhibitor therefore, as expected, we did not find any changes in expression of Mcl-1.  
It has been reported that degradation of anti-apoptotic protein Mcl-1 is controlled by glycogen 
synthase kinase 3 (GSK-3) [28] and the expression of constitutively active GSK-3 decreases 
Mcl-1 expression [28]. GSK3β is a downstream target of PI3k-Akt signaling pathway and 
usually remain active in cells, however PI3K induced activation of Akt results in the 
phosphorylation (S9) of GSK-3β that inhibits its activity [29, 30] as shown in Figure 4A. To 
further dissect the mechanism, we checked the effect of PI3K inhibitors on the phosphorylation 
levels of GSK-3β. Treatment of cells with titrated concentrations of PI3Kα inhibitor (A66) or 
PI3Kβ inhibitor (TGX-221) did not block the S9 phosphorylation of GSK-3β (Figure 4F).  
However, when T-cells were treated with PI3Kδ inhibitor the S9-phosphorylation of GSK-3β 
was blocked only in Tregs (Figure 4G), leading to activation of GSK-3β, which correlates with 
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the decreased Mcl-1 expression (Figure 4E) and survival (Figure 4C) in Tregs. These results 
demonstrate that contrary to Tconv, PI3Kδ is crucial for the regulation of GSK3β and Mcl-1 
dependent survival of Tregs. On the other hand, PI3Kα and PI3Kβ as single isoforms are not 
crucial in the regulation of either Tconv or Tregs. 
 
PI3Kδ is required for the GSK-3b and Mcl-1 dependent survival pathway in Tconvs, and is 
compensated by PI3Kα and PI3Kβ 
We have shown that inhibition of PI3Kδ selectively activates GSK-3β in Tregs, which favors the 
degradation of anti-apoptotic protein Mcl-1 leading to the decreased survival of Tregs, and had 
no effect on Tconvs. To understand the role of PI3K isoforms in the regulation of survival in 
Tconvs, we first examine the effect of PAN PI3K inhibitor. We found that, survival pathway of 
Tconvs is dependent on PAN class IA PI3K isoforms (Figure 5A) inhibition of PAN PI3K 
activate GSK-3β in Tconvs which favors the degradation of anti-apoptotic protein Mcl-1 leading 
to the decreased survival of Tconvs (Figure 5B) and induced apoptosis (Supplementary figure 
S7C). We next investigated whether inhibition of any 2 PI3K isoforms affect survival of Tconvs. 
We found that combining inhibition of both PI3Kα and PI3Kβ did not induce apoptosis and did 
not affect the survival (Figure 5C and supplementary figure S7B). As expected, there was no 
effect on Mcl-1 and pGSK-3β (Figure 5D), which further provide evidences that, in absence of 
PI3Kα and PI3Kβ, PI3Kδ is sufficient to regulate the survival of Tconvs. 
On the other hand, combining PI3Kδ inhibitor with either PI3Kα or PI3Kβ inhibitor 
significantly reduced the survival (Figure 5C), induces apoptosis (supplementary figure S7C), 
and decreased Mcl-1protein with inhibited pGSK-3β of Tconvs (Figure 5D).  
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Together, all these data suggest that PI3Kδ is  sufficient for survival signaling in Tconvs, 
however, in contrast to Tregs, in Tconvs, PI3Kα and PI3Kβ combined can compensate for the 
absence of PI3Kδ (Figure 5E).  
 
Inhibition of PI3Kδ  enhances antigen immune response and synergizes with vaccine for 
better tumor response.  
We evaluated the anti-tumor therapeutic response of the addition of PI3Kδ inhibition to a tumor 
specific peptide vaccine (E7) in TC-1 mouse tumor model. Tumor cells were implanted on day 0 
and treatment was initiated when tumors reached 3-5mm in diameter. Tumor bearing mice 
received CAL-101 every third day and were treated with two doses of a peptide vaccine (Figure 
6A). Tumor growth and survival were monitored. We found that CAL-101 in combination with 
vaccine lead to significant slowdown of tumor progression (Figure 6B) associated with 
prolonged survival (Figure 6C). These data demonstrate that the combinational treatment of 
vaccine with Cal-101 is a therapeutically potent strategy.  
To understand the immune mechanisms leading to the therapeutic efficacy observed with the 
combination of CAL-101 and vaccine treatment, we next profiled the tumor-infiltrating immune 
cells. Tumor cells were implanted on day 0 and treatment was initiated when tumor reached 3-
5mm in diameter. Tumor bearing mice received CAL-101 every third day and were treated with 
two dose of an E7 peptide vaccine (Figure 6A). Mice were sacrificed and tumors were harvested 
for evaluation of tumor-infiltrating T-cell three days after the second vaccination. There were no 
significant differences in tumor volume between different groups at this stage. Administration of 
Cal-101, vaccine and their combination significantly enhanced the numbers of tumor-infiltrating 
immune cells (CD45+ cells) (Figure 6D). The infiltration of CD3+ T-cells was significantly 
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higher in the groups that received the vaccine treatment (vaccine alone or in combination) 
(Figure 6E). A similar effect was observed on tumor-infiltrating CD8+ T-cells, where treatment 
with the vaccine alone or with its combination with Cal-101 significantly increased the total 
number of tumor infiltrating CD8 T-cells (Figure 6F) and more specifically, the antigen (E7) 
specific CD8 T-cells (Figure 6G).  
Since the vaccine alone treatment and its combination with CAL-101 have similar effect on 
tumor infiltration of total and antigen specific CD8T-cells, we explored the possible immune 
mechanisms that leading to the superior therapeutic efficacy of the combination treatment.  We 
profiled the tumor-infiltrating CD4+ T-cells (both Tconvs and Tregs). While neither the vaccine 
alone nor its combination with CAL-101 affected the numbers of tumor-infiltrating Tconvs 
(Figure 6H), a significant decrease in Tregs was observed with CAL-101 and its  combination 
with vaccine (Figure 6I).  
Additionally, as a result of the increase in CD8 T-cell and E7 specific CD8 T-cells, the 
combination of CAL-101 and vaccine treatment showed a significant increase in CD8/Tregs ratio 
(Figure 6J) and E7 specific CD8/Tregs (Figure 6K) and Granzyme positive CD8 cells when 
compared to control groups. 
These data demonstrate that targeting Tregs using Cal-101 enhances the antitumor therapeutic 
efficacy of vaccine treatments and exert effective anti-tumor immune response through an 
increase of tumor-infiltrating Granzyme positive CD8 T-cells, suggesting that this effect is 
predominantly facilitated by addition of Cal-101 to vaccine treatment.  
Although the number of tumor infiltrating CD8 T-cells was significantly higher in all the groups 
that received the vaccine treatment, the therapeutic efficacy was only observed in combination 
with the PI3Kδ inhibitor as a direct result of its inhibition of Tregs. This resulted in a significant 
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reduction of the suppressive effect exerted by Tregs, enabling the CD8 T-cells to effectively 
target the tumor cells. 
 
Discussion 
Here, we have provided evidence that Tregs and Tconvs are differentially regulated by Class IA 
PI3K isoforms. We show that selective inhibition of PI3Kα or PI3Kβ isoforms does not impair 
downstream signaling, proliferation or survival in either Tregs or Tconvs.  
In contrast, inhibition of PI3Kδ selectively affects downstream signaling of TCR in Tregs but not 
Tconvs, leading to inhibition of phosphorylation of Akt and S6 and abrogating their downstream 
biological effects on proliferation and survival. This indicates that Treg TCR downstream 
signaling, proliferation and survival are dominantly dependent on PI3Kδ.  
On the other hand, we show that none of the PI3K isoforms are dominant in Tconv, where the 
inhibition of any single isoform in Tconvs does not affect downstream pathway activation, 
proliferation, or survival.  However, Tconvs are significantly suppressed with the simultaneous 
inhibition of PI3Kδ along with either PI3Kα or PI3Kβ. No such effect was observed after the 
combined PI3Kα and PI3Kβ inhibition. These data suggest that, similar to Tregs, PI3Kδ is 
sufficient for activation, proliferation and survival of Tconvs, but in contrast to Tregs, PI3Kα and 
PI3Kβ can compensate for the absence of PI3Kδ in Tconvs.  Figuer 7 illustrates the model of 
PI3K regulation of TCR signaling and downstream biologic outcome in Tregs and Tconv.  
Naïve CD4 T-cells have a central role in adaptive immunity, since they provide essential help for 
both cytotoxic T-cell- and antibody-mediated responses. The naïve CD4+ T-cells can 
differentiate into several lineages with distinct effector functions. We speculate that, the 
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compensatory mechanism of class IA PI3K isoform could be required for naïve CD4 T-cells to 
differentiate into different effector T-cells.  
 
We further dissected the downstream effect of these PI3K isoforms on the molecular mediators 
of Treg and Tconv cell survival pathways. T-cell survival is controlled by the anti-apoptotic Mcl-
1 protein, which is regulated by GSK3β.   PI3K-Akt signaling is known to control the 
phosphorylation and inactivation of GSK3β [Figure 5].  Here we show that Mcl-1 stability is 
differentially regulated by class IA PI3K isoforms in Tregs and Tconvs, namely through the 
regulation of GSK-3β-mediated degradation of Mcl-1, reflecting the dichotomous control of 
these isoforms to survival. We found that inhibiting PI3Kδ is sufficient to lead to GSK-3β 
activation resulting in the subsequent degradation of Mcl-1 in Tregs, but not the inhibition of 
either PI3Kα or PI3Kβ. We further show that the inhibition of a single class IA PI3K isoform in 
Tconvs does not affect GSK3b, Mcl-1 and thus their survival.  However, downstream survival 
signaling in Tconvs, GSK-3β phosphorylation and Mcl-1 degradation are significantly inhibited 
with the PAN PI3K inhibition or simultaneous inhibition of PI3Kδ along with either PI3Kα or 
PI3Kβ.  No such effect was observed after the combined PI3Kα and PI3Kβ inhibition. These 
data are consistent with the effect of PI3K isoforms on the survival of Tconv and Tregs (figure 
7).   
We further demonstrate that the in vitro understanding of the PI3K isoforms on the Tregs and 
Tconv cells also reflected in-vivo.  Animal treated with PI3Kδ isoform inhibitors showed 
significant decrease in Treg numbers and proliferation in vivo, but not when treated with PI3Kα 
or PI3Kβ.  Furthermore, PI3Kδ inhibitors did not affect neither CD4+Foxp3- nor CD8 T-cells.  
Importantly, we also showed that these finding translated into therapeutic efficacy.   We found 
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that inhibiting PI3Kδ with CAL101 synergistically enhanced the tumor suppression and survival 
effect of antigen specific vaccine. While evaluating immunologic mechanisms responsible for 
this potent therapeutic outcome, we found that CAL-101 resulted in decreasing Tregs tumor 
infiltration resulting in significant increase of tumor-infiltrating antigen specific CD8 T-cells. 
Based on above, here we show the molecular reasons that Tregs but not Tconv are depended on 
PI3Kδ and that such findings can have a major translational and clinical therapeutic impact. 
Accordingly, The differential regulation of the PI3K isoforms between Tregs and Tconvs 
presents a powerful approach to selectively mitigate Tregs and modulate CD4 T-cells. Targeting 
PI3Kδ can preferentially inhibit proliferation and induce cell death of Tregs while having no 
effects on Tconvs. Therefore, targeting PI3Kδ can be used as an immune-modulating mechanism 
in a variety of clinical settings to enhance anti-cancer immune therapy.  
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Figure Legends: 
Figure 1. Regulatory T-cells are more sensitive to PI3Kδ inhibition in vitro. FACS-sorted 
Tregs and Tconvs from WT B16 (foxp3-GFP) mice (A-E), WT B16 and PI3Kδ KO mice (F & 
G) and Human PBMC (H&I)  were plated on anti-CD3-coated plates and cultured in activation 
media (IL2 and anti-CD28) without inhibitors (DMSO, 0nM) and with inhibitors for 72 hrs. For 
negative control (Non-stimulated-NS) cells were left in media containing IL-2 for 72hrs. 
Intracellular phosphorylation of (A-C)  Akt (S473) (D) S6 (S244) and (E) proliferation in live 
gated cells was measured by flow cytometry of Tregs and Tconvs treated with A66 (PI3Kα 
inhibitor), TGX-221 (PI3Kβ inhibitor), and CAL-101 (PI3Kδ inhibitor) and normalized for three 
independent experiments.  Intracellular level of pAkt (S473) and proliferation in live gated cells 
was measured by flow cytometry of Tregs and Tconvs from (F & G) WT B16 and PI3Kδ KO 
mice, (H & I) human Tregs and Tconvs treated with CAL-101 (PI3Kδ inhibitor)respectively.  
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Figure 2.  Class IA PI3K isoforms differentially regulate T-cell subsets in vivo.  C57BL/6 
mice were injected s.c with 70,000 TC-1 cells. On day 10, all mice developed visible tumors of 
equal size. (A) Mice were grouped and injected i.p. with either 2mg/kg or 10mg/kg CAL-101, 
A66, or TGX-221 dissolved in 10% of DMSO. (B) Percentage of Tregs in tumor bearing mice on 
day 10 compared to non-tumor bearing mice (C) Protein lysate were prepared from TC-1 cells, 
separated by SDS-PAGE and immunoblotted with Class IA isoform specific antibodies; actin 
was used as loading control. The percentage of (D)Tregs (CD4+Foxp3+) on day 3 of treatment 
(E) Tregs (CD4+Foxp3+) on day 6 of treatment (F) CD4+ cells on day 3 of treatment and (G) 
CD4+ Foxp3–cells on day 3 of treatment and (H) CD8+ cells  on day 3 of treatment were 
analyzed by flow cytometry. The percentage of cells was normalized and presented as mean ± 
SD . Representative data from 2 independent experiments are shown (3-5 mice for each group 
per experiment).  Statistical significance was determined by one-way ANOVA with Tukey’s 
multiple comparison test (*, p <0.05; **, p <0.01; ***, p < 0.001).   
 
 
Figure 3. Class IA PI3K isoforms have redundant functions in TCR-mediated activation 
and proliferation in conventional T-cells. (A-F) FACS sorted Tconvs (CD4+ Foxp3– )(treated 
with (A-C) GDC-0941 (PAN PI3K inhibitor) or (D-F) combinations of inhibitors including A66 
PI3Kα inhibitor +TGX-221 PI3Kβ inhibitor; A66 PI3Kα inhibitor + CAL-101 PI3Kδ inhibitor;  
and TGX-221 PI3Kβ inhibitor+ CAL-101 PI3Kδ inhibitor for 72 hours were harvested and (A & 
D) pAkt (S473), (B & E) pS6 (S244) and (C & F) proliferation were measured on live gated 
cells using flow cytometry and normalized for three independent experiments. (G) FACS sorted 
Tconvs from PI3Kδ KO mice were treated with,  A66 PI3Kα inhibitor, TGX-221 PI3Kβ 
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inhibitor, A66 PI3Kα inhibitor +TGX-221 PI3Kβ inhibitor and GDC-0941 (PAN PI3K inhibitor) 
and proliferation were measured on live gated cells using flow cytometry and normalized for two 
independent experiments.   
 
Figure 4. Inhibition of PI3Kδ affects GSK-3β and Mcl-1 dependent survival of Tregs but 
not Tconvs. 
 (A-C) Cells were washed and stained for Live/Dead and fixed. Viability was measured by flow 
cytometry of Tregs and Tconvs treated with (A) A66 (a PI3Kα inhibitor), (B) TGX-221 (a PI3Kβ 
inhibitor), and (C) CAL-101 (a PI3Kδ inhibitor). The results normalized for three independent 
experiments. (D-G) Cell lysates prepared on day 3 (72hrs) of treatment from Tregs and Tconvs 
were separated by SDS-PAGE and immunoblotted with specific antibodies (Mcl-1) or GSK-3β 
(pS9); actin was used as loading control. (H) Schematic presentation showing the role of PI3K in 
regulation of proliferation, cell death and survival.   
 
 
Figure 5. Class IA PI3K isoforms compensate for GSK-3β and Mcl-1 dependent survival of 
Tconvs. 
 Cells were washed and stained for Live/Dead and fixed. Viability was measured by flow 
cytometry of Tconvs treated with (A) GDC-0941 (PAN PI3K inhibitor) or (C) combinations of 
inhibitors including, A66 a PI3Kα inhibitor +TGX-221 a PI3Kβ inhibitor, A66 a PI3Kα inhibitor 
+ CAL-101 a PI3Kδ inhibitor, TGX-221 a PI3Kβ inhibitor + CAL-101 a PI3Kδ inhibitor. (B & 
D) In a separate experimenT-cell lysates prepared on day 3 (72hrs) of treatment from Tconvs 
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were separated by SDS-PAGE and immunoblotted with specific antibodies (Mcl-1) or GSK-3β 
(pS9); actin was used as loading control.  
 
 
 
Figure 6.  Combination of vaccine with CAL-101 provides potent anti-tumor therapeutic 
efficacy. A. C57BL/6 mice (n=5/group) were injected s.c. in the right flank with 7x104 TC-1 
cells. Mice from appropriate groups were injected weekly with vaccine (s.c.) or DMSO 5% as a 
control. CAL-101 was injected (i.p.) every third day starting on Day 6 after tumor implantation 
throughout the experiment. B. Plots represent average tumor volumes of mice for each group. C. 
Kaplan–Meier plot of the overall survival. Statistical significance was determined by Log-rank 
(Mantel-Cox) test.   
C57BL/6 mice (n=5/group) were injected with 7x104 TC-1 cells and treated as for Figure 4, and 
tumor-infiltrating (D) Hematopoietic cells (CD45+) (E) T-cells (CD45+CD3+) (F) CD8 T-cells 
and (G) antigen specific CD8 T-cells (H) CD4+Foxp3- (I) CD4+Foxp3+ (J) Ratio of CD8/Tregs 
(K) Ratio of antigen specific CD8/Tregs were analyzed in tumor homogenates by flow cytometry 
as described in Methods section. The absolute numbers of tumor-infiltrating cells were 
standardized per 106 of total live gated cells. *p<0.05, **p<0.01, ***p<0.001.  
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Figure 7. A Model for the differential role of class 1A PI3K isoforms in modulating 
regulating the TCR signaling, proliferation and Survival of Tregs and Tconvs. PI3Kδ 
isoform is sufficient for TCR downstream signaling, proliferation and survival for either Tconvs 
or Tregs. In Tregs, however, PI3Kδ is a dominant isoform, where Tregs are fully dependent on 
PI3Kδ to regulate these properties as PI3Kα and PI3Kβdo not play any role in these biologic 
processes.  On the other hand, in Tconvs, the two other isoforms, PI3Kα and PI3Kβ combined, 
provide redundant pathway to PI3Kδ in the regulation of TCR signaling, proliferation and 
survival.  This dichotomy applies to downstream TCR signaling regulating pS6 phosphorylation 
controlling proliferation and applies to the phosphorylation of GSK3β controlling downstream 
degradation of the anti apoptotic protein Mcl-1 and downstream survival pathway.  
 
 







